EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor (EGFR) mutation represents the most frequent driver-gene alteration in non-small cell lung cancer (NSCLC), and 90% of EGFR mutations involving a deletion within exon 19 (19del) or a leucine-to-arginine substitution in exon 21 (L858R) [1, 2].